1. Burnet FM.The concept of immunological surveillance.Prog Exp Tumor Res，1970，13，：1-27.

2. Hanahan D，Weinberg RA.Hallmarks of cancer：the next generation.Cell，2011，144：646-674.

3. Dunn GP，Bruce AT，Ikeda H，Old LJ，Schreiber RD.Cancer immunoediting：from immunosurveillance to tumor escape. Nat Immunol，2002，3：991-998.

4. Dunn GP，Old LJ，Schreiber RD.The three Es of cancer immunoediting.Annu Rev Immunol，2004，22：329-360.

5. Winter H，van den Engel NK，Ruttinger D，Schmidt J，Schiller M，Poehlein CH，Lohe F，Fox BA，Jauch KW，Hatz RA，Hu HM.Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines.J Transl Med，2007，5：56.

6. Martorelli D，Muraro E，Merlo A，Turrini R，Rosato A，Dolcetti R.Role of CD4 ⁺cytotoxic T lymphocytes in the control of viral diseases and cancer.Int Rev Immunol，2010，29：371-402.

7. Xie Y，Akpinarli A，Maris C，Hipkiss EL，Lane M，Kwon EK，Muranski P，Restifo NP，Antony PA.Naive tumor-specific CD4（+）T cells differentiated in vivo eradicate established melanoma.J Exp Med，2010，207：651-667.

8. Mosmann TR，Cherwinski H，Bond MW，Giedlin MA，Coffman RL.Two types of murine helper T cell clone.I.Definition according to profiles of lymphokine activities and secreted proteins.J Immunol.1986.136：2348-2357.

9. Zhu J，Yamane H，Paul WE.Differentiation of effector CD4 T cell populations（*）.Annu Rev Immunol，2010，28：445-489.

10. Protti MP，Monte LD，Lullo GD. Tumor antigen-specific CD4+ T cells in cancer immunity：from antigen identification to tumor prognosis and development of therapeutic strategies.Tissue Antigens，2014，83：237-246.

11. Jemal A，Bray F，Center MM，Ferlay J，Ward E，Forman D：Global cancer statistics.CA Cancer J Clin 2011；61：69-90.

12. van der Bij GJ，Oosterling SJ，Beelen RH，Meijer S，Coffey JC，van Egmond M.The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer.Ann Surg，2009，249：727-734.

13. Yamaguchi K，Takagi Y，Aoki S，Futamura M，Saji S.Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection.Ann Surg，2000，232：58-65.

14. Conzelmann M，Linnemann U，Berger MR.Detection of disseminated tumour cells in the liver of cancer patients.Eur J Surg Oncol，2005，31：977-985.

15. Peach G，Kim C，Zacharakis E，Purkayastha S，Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers：a systematic review. Br J Cancer，2010，102：1327-1334.

16. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res，2007，134：21-33.

17. Belizon A，Balik E，Feingold DL，Bessler M，Arnell TD，Forde KA，Horst PK，Jain S，Cekic V，Kirman I，Whelan RL.Major abdominal surgery increases plasma levels of vascular endothelial growth factor：open more so than minimally invasive methods.Ann Surg，2006，244：792-798.

18. Neeman E，Ben-Eliyahu S.Surgery and stress promote cancer metastasis：new outlooks on perioperative mediating mechanisms and immune involvement.Brain Behav Immun，2013，30 Suppl：S32-40.

19. Snyder GL，Greenberg S.Effect of anaesthetic technique and other perioperative factors on cancer recurrence.Br J Anaesth，2010，105：106-115.

20. Whelan P，Morris PJ. Immunological responsiveness after transurethral resection of the prostate：general versus spinal anaesthetic.Clin Exp Immunol，1982，48：611-618.

21. Homburger JA，Meiler SE.Anesthesia drugs，immunity，and long-term outcome.Curr Opin Anaesthesiol，2006，19：423-428.

22. Lin L，Liu C，Tan H，Ouyang H，Zhang Y，Zeng W.Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma：a retrospective analysis.Br J Anaesth，2011，106：814-822.

23. Chen WK，Miao CH.The effect of anesthetic technique on survival in human cancers：a meta-analysis of retrospective and prospective studies.PLoS One，2013，8：e56540.

24. Myles PS，Peyton P，Silbert B，Hunt J，Rigg JR，Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival：randomised trial.BMJ，2011，342：d1491.

25. Kennedy BC，Hall GM. Neuroendocrine and inflammatory aspects of surgery：do they affect outcome？Acta Anaesthesiol Belg，1999，50：205-209.

26. Chrousos GP.The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.N Engl J Med，1995，332：1351-1362.

27. Ahlers O，Nachtigall I，Lenze J，Goldmann A，Schulte E，Hohne C，Fritz G，Keh D. Intraoperative thoracic epidural anaesthesia attenuates stress-induced immunosuppression in patients undergoing major abdominal surgery.Br J Anaesth，2008，101：781-787.

28. Green JS，Tsui BC.Impact of anesthesia for cancer surgery：Continuing professional development.Can J Anaesth，2013，60：1248-1269.

29. Xu YJ，Chen WK，Zhu Y，Wang SL，Miao CH.Effect of thoracic epidural anaesthesia on serum vascular endothelial growth factor C and cytokines in patients undergoing anaesthesia and surgery for colon cancer. Br J Anaesth，2014， 113suppl1：i49-55.

30. Wada H，Seki S，Takahashi T，Kawarabayashi N，Higuchi H，Habu Y，Sugahara S，Kazama T. Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology，2007，106：499-506.

31. Tavare AN，Perry NJ，Benzonana LL，Takata M，Ma D. Cancer recurrence after surgery：direct and indirect effects of anesthetic agents.Int J Cancer，2012，130：1237-1250.

32. Bidlack JM，Khimich M，Parkhill AL，Sumagin S，Sun B，Tipton CM.Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol，2006，1：260-269.

33. Feng Y，He X，Yang Y，Chao D，Lazarus LH，Xia Y.Current research on opioid receptor function. Curr Drug Targets，2012，13：230-246.

34. Afsharimani B，Cabot P，Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev，2011，30：225-238.

35. Ninkovic J，Roy S.Role of the mu-opioid receptor in opioid modulation of immune function.Amino Acids，2013，45：9-24.

36. Houghtling RA，Mellon RD，Tan RJ，Bayer BM. Acute effects of morphine on blood lymphocyte proliferation and plasma IL-6 levels.Ann N Y Acad Sci，2000，917：771-777.

37. Shavit Y，Ben-Eliyahu S，Zeidel A，Beilin B.Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats.Dose and timing study.Neuroimmunomodulation，2004，11：255-260.

38. Gaspani L，Bianchi M，Limiroli E，Panerai AE，Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats.J Neuroimmunol，2002，129：18-24.

39. Sacerdote P，Bianchi M，Gaspani L，Manfredi B，Maucione A，Terno G，Ammatuna M，Panerai AE.The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients.Anesth Analg，2000，90：1411-1414.

40. Benzonana LL，Perry NJ，Watts HR，Yang B，Perry IA，Coombes C，Takata M，Ma D.Isoflurane，a commonly used volatile anesthetic，enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology，2013，119：593-605.

41. Kvolik S，Glavas-Obrovac L，Bares V，Karner I.Effects of inhalation anesthetics halothane，sevoflurane，and isoflurane on human cell lines.Life Sci，2005，77：2369-2383.

42. de Rossi LW，Brueckmann M，Rex S，Barderschneider M，Buhre W，Rossaint R. Xenon and isoflurane differentially modulate lipopolysaccharide-induced activation of the nuclear transcription factor KB and production of tumor necrosis factor-alpha and interleukin-6 in monocytes. Anesth Analg，2004，98：1007-1012.

43. Ren XF，Li WZ，Meng FY，Lin CF.Differential effects of propofol and isoflurane on the activation of T-helper cells in lung cancer patients.Anaesthesia，2010，65：478-482.

44. Inada T，Kubo K，Shingu K.Possible link between cyclooxygenase-inhibiting and antitumor properties of propofol. J Anesth，2011，25：569-575.

45. Wheeler DW，Thompson AJ，Corletto F，Reckless J，Loke JC，Lapaque N，Grant AJ，Mastroeni P，Grainger DJ，Padgett CL，O’Brien JA，Miller NG，Trowsdale J，Lummis SC，Menon DK，Beech JS.Anaesthetic impairment of immune function is mediated via GABA（A）receptors.PLoS One，2011，6：e17152.

46. Garib V，Lang K，Niggemann B，Zanker KS，Brandt L，Dittmar T.Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells.Eur J Anaesthesiol，2005，22：609-615.

47. Ohta N，Ohashi Y，Fujino Y.Ketamine inhibits maturation of bone marrow-derived dendritic cells and priming of the Th1-type immune response.Anesth Analg，2009，109：793-800.

48. Ohta N，Ohashi Y，Takayama C，Mashimo T，Fujino Y.Midazolam suppresses maturation of murine dendritic cells and priming of lipopolysaccharide-induced t helper 1-type immune response.Anesthesiology，2011，114：355-362.

49. Son KA，Kang JH，Yang MP.Ketamine inhibits the phagocytic responses of canine peripheral blood polymorphonuclear cells through the upregulation of prostaglandin E2 in peripheral blood mononuclear cells in vitro. Res Vet Sci，2009，87：41-46.

50. Melamed R，Bar-Yosef S，Shakhar G，Shakhar K，Ben-Eliyahu S.Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine，thiopental，and halothane，but not by propofol：mediating mechanisms and prophylactic measures.Anesth Analg，2003，97：1331-1339.

51. Sakaguchi M，Kuroda Y，Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg，2006，102：1103-1107.

52. Lucchinetti E，Awad AE，Rahman M，Feng J，Lou PH，Zhang L，Ionescu L，Lemieux H，Thebaud B，Zaugg M.Antiproliferative effects of local anesthetics on mesenchymal stem cells：potential implications for tumor spreading and wound healing.Anesthesiology，2012，116：841-856.

53. Werdehausen R，Braun S，Fazeli S，Hermanns H，Hollmann MW，Bauer I，Stevens MF.Lipophilicity but not stereospecificity is a major determinant of local anaesthetic-induced cytotoxicity in human T-lymphoma cells.Eur J Anaesthesiol，2012，29：35-41.

54. Forget P，Collet V，Lavand’Homme P，De Kock M.Does analgesia and condition influence immunity after surgery？Effects of fentanyl，ketamine and clonidine on natural killer activity at different ages.Eur J Anaesthesiol，2010，27：233-240.

55. Harris RE：Cyclooxygenase-2（cox-2）blockade in the chemoprevention of cancers of the colon，breast，prostate，and lung.Inflammopharmacology 2009；17：55-67.

56. Farooqui M，Li Y，Rogers T，Poonawala T，Griffin RJ，Song CW，Gupta K.COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis，tumour growth，metastasis and mortality，without compromising analgesia.Br J Cancer，2007；97：1523-1531.